Nydannelse af blodkar i tumorer: Nye muligheder for behandling

Ugeskrift for Laeger

Volumn 161, Issue 20, 1999, Pages 2929-2933

  Lund, Eva Løbner ^a   Kristjansen, Paul E G ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; GROWTH FACTOR RECEPTOR; GROWTH INHIBITOR;

ARTICLE; BIOSYNTHESIS; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ENDOTHELIUM, VASCULAR; GROWTH INHIBITORS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, GROWTH FACTOR;

EID: 0033577608     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
2. Hobson B, Denekamp J. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer 1984; 49: 405-13.
3. Ellis V, Danr K. The urokinase receptor and the regulation of cell surface plasminogen activation. Fibrinolysis 1992; 6: 27-34.
4. Edwards DR, Murphy G: Proteases - invasion and more - The AACR & APMIS conference in Nyborg Strand, Denmark. Nature 1998; 394: 527-8.
5. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.
6. Enholm B, Paavonen K, Ristimaki A, Kumar V, Gunji Y, Klefstrom J et al. Comparison of VEGF, VEGF-B. VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 1996; 93: 2576-81.
7. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997; 276: 1423-5.
8. Pepper MS, Ferrara N, Orci L, Montesano R: Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commum 1992; 189: 824-831.
9. Möhle R, Green D, Moore MA, Nachman RL, Rafii S: Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997; 94: 663-8.
10. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
11. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-4.
12. Van Meir EG, Polverini PJ, Chazin W, Su Huang HJ, de Tribolet N, Cavenee WK. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nature Genet 1994; 8: 171-6.
13. Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 1996; 56: 1324-30.
14. Nelson NJ. Inhibitors of angiogenesis enter phase III testing. J Natl Cancer Inst 1998; 90: 960-3.
15. Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfenato J, Brown P et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Canc Res 1998; 4: 1101-9.
16. Teicher BA, Sotomayor EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 1992; 52: 6702-4.
17. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba M, Stellato KA. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998; 394: 287-91.
18. Jain RK, Schienger K, Höckel M, Yuan F. Quantitative angiogenesis assays: progress and problems. Nature Med 1997; 3: 1203-8.